EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against Acinetobacter baumannii

Mathilde Lacroix, Jérémy Moreau, Claudia Zampaloni, Caterina Bissantz, Hélène Mirfendereski, Hamasseh Shirvani, Sandrine Marchand iD, William Couet iD, Alexia Chauzy iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01535-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Mathilde Lacroix und 8 weiteren Autor:innen. Beteiligte Einrichtung: Université de Poitiers INSERM, PHAR2, Poitiers, Nouvelle-Aquitaine, France. Hauptthemen laut MEDLINE: Polymyxin B, Acinetobacter baumannii, Anti-Bacterial Agents, Mucins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association Nationale de la Recherche et de la Technologie, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The antibacterial efficacy of polymyxins in lungs may be impacted by mucin. The aim of this study was to characterize in vitro the effect of mucin on polymyxin B (PMB) activity against two multidrug-resistant Acinetobacter baumannii strains isolated from a patient before (AB121-D0) and after colistin treatment (AB122-D12), using a pharmacokinetic/pharmacodynamic (PK/PD) modeling approach. PMB binding to mucin was characterized by ultracentrifugation in cation-adjusted Mueller-Hinton broth (CAMHB) supplemented with 1% mucin. Time-kill (TK) experiments were performed in CAMHB, with 1% mucin or without as control, and with PMB total concentrations ranging from 0.25 to 512 mg/L based on the strain’s minimum inhibitory concentration (MIC). For each strain, TK data were modeled based on unbound PMB concentrations. Bacterial resistance to PMB was investigated via MIC and whole genome sequencing from bacteria that regrew in the presence of antibiotics at the end of the TK experiments. PMB unbound fraction increased nonlinearly from 6% to 60% when total concentration increased from 0.5 to 512 mg/L. In addition to binding to PMB, mucin had an impact on PMB activity, which differed between the two strains. For AB121-D0, PMB activity increased in the presence of mucin resulting in a reduction of the bacterial regrowth, whereas for AB122-D12, a decrease in PMB activity was observed. Mutations in genes involved in PMB resistance appeared randomly and explained only partially the bacterial regrowth observed in TK with antibiotics. This study showed that PMB binding to mucin had a real and important impact but was not the only factor explaining the impaired PMB efficacy in the presence of mucin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymyxin BAcinetobacter baumanniiAnti-Bacterial AgentsMucinsMicrobial Sensitivity TestsHumansDrug Resistance, Multiple, BacterialColistinAcinetobacter Infections

Stichwörter der Autor:innen

A. baumanniimucinpolymyxin Bsemi-mechanistic PK/PD modeling

Substanzen

Polymyxin BAnti-Bacterial AgentsMucinsColistin

Autor:innen und Institutionen

  • Université de Poitiers INSERM, PHAR2, Poitiers, Nouvelle-Aquitaine, France.
  • Institut Roche-Boulogne-Billancourt, Boulogne-Billancourt, France.
  • Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Basel, Basel-Stadt, Switzerland.
  • Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Basel-Stadt, Switzerland.
  • Département de Pharmacocinétique et Toxicologie, CHU Poitiers, Poitiers, Nouvelle-Aquitaine, France.

ORCID-Profile: Sandrine Marchand, William Couet, Alexia Chauzy

Förderung

  • Association Nationale de la Recherche et de la Technologie
  • Roche

Zitieren

APA

Lacroix, M., Moreau, J., Zampaloni, C., Bissantz, C., Mirfendereski, H., Shirvani, H., Marchand, S., Couet, W., & Chauzy, A. (2025). In vitro pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01535-24

Vancouver

Lacroix M, Moreau J, Zampaloni C, Bissantz C, Mirfendereski H, Shirvani H, et al. In vitro pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01535-24

BibTeX
@article{Lacroix2025,
  author = {Lacroix, Mathilde and Moreau, Jérémy and Zampaloni, Claudia and Bissantz, Caterina and Mirfendereski, Hélène and Shirvani, Hamasseh and Marchand, Sandrine and Couet, William and Chauzy, Alexia},
  title = {In vitro pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against Acinetobacter baumannii},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01535-24}
}
Kostenlos starten →